Mass coronavirus testing plans unrealistic, warns Italian biotech boss

The mass testing that is central to lockdown exit plans in many countries is unrealistic because of high costs and lack of production capacity, according to the boss of an Italian biotech company that supplies tests around the world. Carlo Rosa, chief executive of DiaSorin, which sells Covid-19 diagnostic and antibody tests, said demand far exceeded supply and the percentage of people who had contracted the virus globally was too low to hope for mass immunity as another way out of restrictive lockdown measures.